Immunogenicity and immunizing protection effect of GAMA gene DNA vaccine on Plasmodium berghei  by Du, Feng et al.
HOSTED BY Contents lists available at ScienceDirect
Asian Paciﬁc Journal of Tropical Medicine 2016; 9(2): 158–163158Asian Paciﬁc Journal of Tropical Medicine
journal homepage: http://ees.elsevier.com/apjtmOriginal research http://dx.doi.org/10.1016/j.apjtm.2016.01.003*Corresponding author: En-Jie Luo, MD., Pathogen Biology Department, China Medical University, No.77, Pu He Rd., Ne
Tel: +86 18900911412
E-mail: enjiecmu@126.com
Peer review under responsibility of Hainan Medical College.
Foundation project: It was supported by National Natural Science Foundation of China (NSFC) (No. 81471978).
1995-7645/Copyright © 2016 Hainan Medical College. Production and hosting by Elsevier B.V. This is an open access artic
creativecommons.org/licenses/by-nc-nd/4.0/).Immunogenicity and immunizing protection effect of GAMA gene DNA vaccine on Plasmodium
bergheiFeng Du1, Si Wang1, Chen Zhao2, Ya-Ming Cao3, En-Jie Luo1*1Department of Pathogen Biology, Basic Medical College of China Medical University, Shenyang City, Liaoning, China
2Inspection Institute of Jilin Medical College, China
3Department of Immunology, Basic Medical College of China Medical University, Shenyang City, Liaoning, ChinaARTICLE INFO
Article history:
Received 15 Nov 2015
Received in revised form 20 Dec
2015
Accepted 30 Dec 2015







Objective: To explore the effect of immunogenicity and immunizing protection of
GAMA gene DNA vaccine, which was related with merozoite, ookinete and sporozoite
invasion.
Methods: Gene fragments were obtained using PCR technique and eukaryotic expres-
sion vector (containing immunostimulatory sequence) was built. BALB/c mice were
divided into PBS control group, empty vector control group and study group and were
immunized at week 0, 3 and 6 respectively. Blood was collected 2 weeks after each
immunization and serum was separated to detect the IgG, IgG1 and IgG2a levels. Spleen
of mice was obtained for preparation of splenic mononuclear cell and the cytokine IL-4
and IFN-g levels were detected. Indirect immunoﬂuorescence and western blot were
employed to verify the speciﬁcity of antiserum. Sporozoite and merozoite invasion were
used respectively to detect the immune protective effect 2 weeks after the third immu-
nization. Ookinete conversion rate in vitro and oocyst numbers of mosquito stomach were
observed to evaluate the transmission-blocking levels.
Results: In GAMA DNA vaccine group: antiserum could be combined with recombinant
protein speciﬁcally and green ﬂuorescence signals of merozoite, ookinete and sporozoite
were observable, while speciﬁc fragments and ﬂuorescence signals were not observable in
empty vector group. Compared with control group, speciﬁc IgG in DNA vaccine im-
munity group signiﬁcantly increased (P < 0.01), and IgG1 and IgG2a all increased
(P < 0.01). IL-4, IFN-g content in study group signiﬁcantly increased, compared with
control group (P < 0.01). GAMA DNA vaccine immunity could not obviously block the
erythrocyte-stage infection (caused by sporozoite invasion); compared with control
group, liver worm load was slightly reduced (P < 0.05), and antiserum ookinete numbers
(cultured in vitro) had no signiﬁcant difference with oocyst numbers of mosquito stomach
in DNA vaccine group.
Conclusions: GAMA has good antigenicity, which could stimulate the body to produce
speciﬁc immune responses; while DNA vaccine immunity could not play a good pro-
tective effect, the effect of which is only limited to the slight reduction of liver worm load,
and has no obvious erythrocyte-stage protective effect and transmission-blocking effect.
Therefore, trying other immunization strategies for further research on the value of
GAMA (as multi-stage antigen vaccine and multi-stage combined vaccine components of
the life-cycle of plasmodium) is necessary.w Shenbei District, Shenyang 110122, China.
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Malaria is caused by plasmodium infection and was trans-
mitted by female anopheles. As is estimated by World Health
Organization, there are about 198 million cases around the world
in 2013, among which, about 584000 people die from plas-
modium infection (mainly for children under the age of ﬁve) [1].
The drug resistance of plasmodium and mosquitoes inhibits the
comprehensive control of parasites and disease vectors, which
makes it difﬁcult to effectively control malaria [2–4]. Although
large quantities of promising preclinical studies have been
carried out, there is still no an effective vaccine which could
prevent infection or at least improve malaria clinical disease
development. RTS,S, which could induce the immune
responses of circumsporozoite protein, is a kind of pre-
erythrocytic stage vaccine aiming to prevent from the primary
infection of liver cells and may be the ﬁrst malaria vaccine to
enter into market after ﬁnishing clinical trials [5]. Although
RTS,S could prevent partial malaria infection, especially for
children, and then lower the mortality rate of malaria [6],
developing more effective vaccine for further eliminating
malaria is still necessary [7,8].
DNA vaccine could produce protective immune responses to
various pathogens [9–11]. Among them, there have been four
animal vaccine products with license, namely, equine West
Nile virus vaccine and infectious hematopoietic necrosis virus
vaccine of ﬁsh for infection prevention, vaccine for the
treatment of dog cancer and growth hormone gene therapy for
increasing survival rate of suckling pig. These examples show
that DNA vaccine is effective in various species [11]. DNA
vaccine of plasmodium in the pre-erythrocytic stage, erythro-
cytic stage, sexual stage and multi-stage could also induce
speciﬁc immune responses and protective effect [12–18].
Therefore, DNA vaccine should be one of the most effective
methods for malaria prevention and control.
Plasmodium has complex life-cycle, which could cause
mammalian host infection and mosquito (transmission carrier)
infection, which indicates antigen uniqueness and diversity in
the infection and replication stage and limited the effect of
stage-speciﬁc vaccine [19]. Therefore, multi-stage malaria vac-
cine could achieve higher effects. Multi-stage vaccine is not
only multiple antigens expressed in multiple stages but also
single antigen expressed in multiple stages. GAMA is a kind of
multi-stage expression antigen involved in invasion [20–23].
GAMA is anchored at the top recombiner of merozoite, which
is a kind of GPI-anchored erythrocyte-binding protein, has
expression in ookinete and has important effects during liver
phasic development. The GAMA knockout type oocyst and
sporozoite formation quantities of Plasmodium berghei
(P. berghei) are respectively 22.0% and 0.3% of the wild type
and knockout type sporozoite could not cause vertebrate
infection [20]. In addition, antibody induced by GAMA
(expressed by acellular wheat germ system) has 38% of
invasive inhibition ability and 20% of growth inhibitory
activity in vitro [22].
In this paper, DNA vaccine immunization strategy is
employed to discuss immunogenicity and preventive effect of
GAMA, with P. berghei as model. The immune effects after its
immunization and the multiple-stage immune preventive effects
are evaluated.2. Materials and methods
2.1. Ethical approval
This study was in accordance with the China Medical Uni-
versity laboratory animal ethics standards and laboratory animal
welfare technical operation standard website (http://pwc.cnilas.
org/plus/list.php?tid=1) requirements.
2.2. Bioinformatics analysis
GAMA gene sequence data and gene expression proﬁle of
P. berghei were obtained from PlasmoDB URL (http://
PlasmoDB.org; code: PBANKA_070190). SMART (Simple
Modular Architecture Research Tools) was used for functional
domain prediction. Antigen peptide was predicted by online
antigen prediction software (http://imed.med.ucm.es/Tools/
antigenic.pl) and LASERGENE software. Homologous
sequence comparison [Plasmodium falciparum
(PF3D7_0828800), Plasmodium knowlesi (PKH_050210),
Plasmodium yoelii (P. yoelii) (PY17X_0702200), Plasmodium
chabaudi (PCHAS_093610) and Plasmodium vivax
(PVX_088910)] was conducted by CLUSTALX2 to analyze the
sequence similarity.
2.3. Mice, plasmodium and mosquito
Speciﬁc pathogen free BALB/c mice (5–6 weeks) were
bought from Liaoning Changsheng Biotechnology Co., LTD.
Anopheles stephensi (A. stephensi) was breeded in mosquito
room. P. berghei was used in this study. Sporozoite, which was
used for invasion, was collected from infected mosquito salivary
glands and was placed in 1640 culture medium (contained mice
serum) [24,25].
2.4. Plasmid construction and puriﬁcation
Gene sequence (removed from signal peptide and trans-
membrane domain) was designed as DNA vaccine component
[amino acid site (aa) 22-602]. Termination codon TAA, immu-
nostimulation sequence CpG sequence motif and enzyme
digestion site-BglⅡ were included in reverse primers, and
enzyme digestion site-BamHⅠ was included in forward primers.
The obtained target fragments were connected to the eukaryotic
expression vector VR1020. Fragments [amino acid site (aa) 46-
552] were cloned into prokaryotic expression vector for re-
combinant protein-PbGAMA expression. Gene sequence was
analyzed by the Vector NTI Advance11.5.1 to make sure the
correct code-reading and the expression of fusion tags. DNA
vaccine vector was extracted by Endotoxinfree Plasmid Maxi
Kit (Tiangen) and was dissolved in PBS, and concentration of
which was adjusted to 1 mg/mL.
2.5. Recombinant protein expression
Recombinant protein-PbGAMAwas contained in Escherichia
coliRosetta-gamiB (DE3), which was expressed using 1.0 mM of
isopropylthiogalactoside (20 C) for 6 h. Recombinant protein
was veriﬁed by western blot and was puriﬁed by ion afﬁnity
chromatography using histidine choosing cobalt resin (Sangon).
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BALB/c mice were randomly divided into 3 groups (PBS
control group, empty vector VR1020 control group and VR1020-
PbGAMA immune group). Intramuscular injection of immune
vaccine was carried out at quadriceps femoris site, with once
every three weeks, total immunization for 3 times. Two weeks
after each immunization, serumwas collected from 3mice in each
group and spleen cells were separated for cultivation.
2.7. Analysis of western blot and indirect
immunoﬂuorescence
Western blot was analyzed using prokaryotic expressive re-
combinant protein to verify that DNA vaccine immunization has
produced PbGAMA speciﬁc antibody. After 12% of SDS-PAG
electrophoresis, recombinant protein was transferred onto the
surface of PVDF membrane (Merck). The membrane was sealed
by PBS (contained 5% of skim milk powder) and was nurtured
in VR1020-PbGAMA immune serum and control serum (1:100
dilution) for 1 h respectively. After PBST rinsing, Goat Anti-
Mouse IgG (H+L) (1:10000 dilution, HRP labeled) (Jackson
ImmunoResearch Labs) was added for nurturing. After rinsing,
protein was ﬁxed on the membrane and ECL enhanced chem-
iluminescence reagent kit (Thermo) was used for imaging
analysis by imager (Tanon). Protein molecular weight relative
size was compared and evaluated using PageRuler Prestained
protein molecular weight standard (Thermo). PbGAMA poly-
clonal antiserum was used to carry out the indirect immunoﬂu-
orescence of agamont, ookinete and sporozoite in P. berghei and
to verify the ability of antiserum combining with parasite sur-
face. Agamont, ookinete were cultivated in accordance with
methods illustrated in literature [26] and sporozoite was collected
from the infected mosquito salivary glands. Indirect
immunoﬂuorescence was performed in accordance with
descriptions in literature [27].
2.8. Antibody analysis
Blood was collected from eyeballs two weeks after each
immunization and serum was collected centrifugally for storing
at −70 C. Speciﬁc IgG and IgG1, IgG2a were detected by
ELISA testing [27]. Brief speaking, recombinant protein-
PbGAMA (10 mg/mL) was dissolved in PH9.6 coating solu-
tion, with 100 mL per well for coating ELISA plate. Coating
ELISA plate was washed by PBST (PBS: containing 0.05% of
Tween 20) and sealing solution (PBS: containing 1% of BSA)
was added for 1 h at 37 C. After PBST washing, serum (1:400
dilution) was added for 1 h at 37 C. After plate-washing, HRP-
goat anti-mouse IgG (H+L) (1:2000; Santa) and IgG1, IgG2a
(1:1000; Santa) were added accordingly for 1 h at 37 C.
Absorbance was detected at the absorbance of 450 nm using
soluble TMB color solution.
2.9. Cytokine analysis
Spleen was collected from each group 2 weeks after each
immunization. Splenocyte suspension was prepared based on the
previous descriptions [28] and was spread within 24-well plates,
with 5 × 106 cells in 500 mL of culture medium per well.
Splenocytes were stimulated for 72 h using recombinant protein(10 mg/mL) and positive control was stimulated using ConA
(5 mg/mL). IFN-g and IL-4 in the cultural supernatant were
detected using ELISA kit (450 nm, Thermo).
2.10. Evaluation for erythrocyte-stage preventive effect
Two weeks after the ﬁnal immunization, abdominal eryth-
rocytes of each mouse were infected by 106 P. berghei in both
groups (ten mice in each group). Tail blood of mice was
collected for smearing 1 d after being infected, with giemsa
staining. Under themicroscope, malaria was detected until the
death or recovery of mice.
2.11. Analysis of ookinete development in vitro
Enterocoelia of mice was infected by 1 × 107 plasmodium after
phenylhydrazine processing. Anticoagulation was collected 3 d
after being infected and every 20 mL blood was added into 180 mL
ookinete culture medium. This culture was added to 96-well
plates (contained anti GAMA mice serum and control immune
serum) for 24 h at 19 C, with the serum dilution ratio 1:5, 1:10
and 1:50. After nurturing, this culture was collected centrifugally
(500 ×g, 5 min) and was washed for once using PBS. After its
ﬁxation, Pbs28 McAb 13.1 was used for marking and ookinete
numbers were counted under ﬂuorescence microscope.
2.12. Transmission-blocking analysis of direct mosquito
bites (Direct feeding assay)
As for 3 mice in each group after immunization, phenyl-
hydrazine processing was carried out 10 d after the ﬁnal im-
munization. Three days after that, erythrocytes of mice were
infected by 106 P. berghei. Then 50 A. stephensi which had been
in hunger for 24 h in each group were used to bite the mice.
Mosquitoes were bred using 10% of sugar water under the hu-
midity of 50%–80% and (19–22) C. Ten days after being
infected. Mosquito stomach was dissected and oocyst numbers
were counted. Compared with VR1020 control group, percent-
age loss of oocyst was counted to analyze the blocking levels.
2.13. Analysis of liver-stage worm load in vivo
Caudal vein of mice (3 mice/group) was injected with 1 × 104
sporozoite of P. berghei. About 42 h after being infected, mice
were anaesthetized using chloral hydrate and were put to death
by dislocation of cervical vertebra. The whole liver of mice was
obtained and was put into RNAiso Plus (TaKaRa) for grinding
and blending. After RNA extracting, inverse transcription (Pri-
meScript RT reagent Kit, TaKaRa) was carried out. Reagent-
SYBR Premix EX TaqⅡ (TaKaRa) was used for real-time
quantiﬁcation PCR and analysis. Each sample was repeated
for 3 times. Speciﬁc primers: P. berghei 18S 50-GGA-
GATTGGTTTTGACGTTTATGTG-30; 50-AAGCATTAAA-




GraphPad Prism5.01 software was used for statistical anal-
ysis. Mann-Whitney-U test or Student's t-test were used for




Target protein was obtained by PlasmoDB database
screening. Screening conditions: 1. Target protein had mem-
brane related transmission components like signal peptide,
transmembrane domain, GPI-anchored and plasmodium; 2.
Target protein predicted and involved in the interaction between
adhesion & invasion protein and protein. The screening GAMA
caused the attention due to its multi-stage expression. GAMA of
P. berghei consisted of 625 amino acids, with molecular mass
71.1 kDa, signal peptide 1-21 amino acid residue and trans-
membrane domain: 602-625 amino acid residue. Multiple
sequence comparative analysis showed that GAMA was rela-
tively conservative and the consistency of which reached to
57.4% between parasite species. Two highly conservative seg-
ments were contained in GAMA. Immunogenicity prediction
software indicated that GAMA had better antigenic
characteristics.
3.2. Successful building of recombinant DNA vaccine
22-601 amino acid segments of PbGAMA were connected to
vector VR1020 and recombinant DNA vaccine VR1020-
PbGAMA was built, with correct enzyme digestion identiﬁca-
tion and sequencing. Western blot analysis showed that anti-
serum which was generated by DNA vaccine immunity could be
combined with Escherichia coli expressive recombinant protein
(rPbGAMA, 77 kDa), with no stripes in empty vector group.
Indirect immunoﬂuorescence also showed that antiserum could
be combined with merozoite, ookinete and sporozoite of
P. berghei. Fluorescence could not be detected in control group.
These phenomena and results indicated that VR1020-PbGAMA
DNA vaccine could be expressed effectively in vivo and could
stimulate the body to produce antibody which could recognize
the PbGAMA.
3.3. Cloning, expression and puriﬁcation of PbGAMA
protein
Segments with higher antigenicity (46-552 amino acid) were
selected based on antigen peptide prediction results. Recombi-
nant protein-PbGAMA was expressed in soluble form and was
puriﬁed under natural conditions. Protein which was puriﬁed by
SDS-PAGE electrophoresis was estimated at 77 kDa. Recom-
binant protein could be recognized by the tag antibody of anti-
histidine.
3.4. Antibody responses induced by immunization
The total IgG levels had no obvious changes in PBS group
and empty vector group. The total IgG levels in VR1020-
PbGAMA immune group signiﬁcantly rose, compared with
two control groups after the second immunization (P < 0.05).
IgG subclass levels in VR1020-PbGAMA immune group also
signiﬁcantly rose, compared with control group (P < 0.05).3.5. Analysis of cytokine IL-4 and INF-g induced by
immunization
The immune responses of constructed DNA vaccine were
analyzed and mice in three groups were immunized with PBS,
VR1020 and VR1020-PbGAMA respectively. The IL-4 and
INF-g levels of splenic cell culture supernatant were detected by
ELISA kit two weeks after each immunization. IL-4 and INF-g
levels in VR1020-PbGAMA DNA vaccine immunity group
signiﬁcantly rose, compared with control group (P < 0.05).
3.6. Evaluation on erythrocyte-stage preventive effect
in vivo
Tail blood smearing detection showed that malaria curve was
similar to that in control group. One day after being infected, the
infected erythrocytes in each group could be found in peripheral
blood. Malaria in three groups went up gradually and reached to
the highest level at day 10. This highest level was maintained for
several days until the death of mice. Survival rate between
groups had no difference. Eleven days after being infected, mice
began to die gradually; no survival mice existed in each group
21 d after being infected. The results indicated that VR1020-
PbGAMA DNA plasmid immunization could not effectively
delay or lower the malaria infected by P. berghei and extend the
survival time.
3.7. Evaluation on the transmission-blocking ability
Ookinete conversion rate was detected in vitro to measure the
development and viability of ookinete (contained antiserum).
Compared with control group, ookinete numbers were not
obviously reduced in 24 h ookinete culture with ﬁnal antiserum
concentration 1:5; 1:10 and 1:50. Further transmission-blocking
effect was detected to explain whether antiserum could affect the
recognition and trajection of ookinete and peritrophic matrix and
microvilli. A. stephensi in each group were used to bite the mice
(infected by P. berghei for 3 d) accordingly. The oocyst density
of mosquito stomach in PBS and empty vector group were 41.2
and 35.4, respectively. The oocyst density in study group was
40.0, which was not signiﬁcantly reduced compared with control
group.
3.8. Evaluation on the liver-stage protection
P. berghei 18SrRNA could be detected in uninfected control
group. Compared with infected control group, liver worm load
was slightly reduced in vaccine immunity group. The remaining
5 mice in each group were detected with infected erythrocytes
4 d after being infected. The results showed that VR1020-
PbGAMA DNA vaccine immunization could partly block the
sporozoite invasion and development, but could not prevent
from the blood infection.
4. Discussion
Malaria has brought great threat to the public health and
economic development in the worldwide. After more than half a
century of centralized researches, only one malaria candidate
vaccine ‘RTS,S’ may be registered on the market. However, its
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limited (46% for children with 18 months and only 27% for
infants) [6]. Due to the fact that vaccination without complete
immune protection effect could increase the transmission of
high virulence pathogens [29], the next generation of malaria
vaccine with higher transmission-blocking effect was in ur-
gency. This paper was aimed to illustrate the feasibility of
GAMA as multi-stage candidate vaccine and illustrate whether
GAMA could produce pre erythrocyte-stage and erythrocyte-
stage protective efﬁcacy and had transmission-blocking ability
after immunization.
GAMA had features of candidate vaccine. The antigen
diversiﬁcation of plasmodium was one of the main causes to
inhibit the malaria vaccine research [30]. Multiple sequence
alignment analysis proved that GAMA was relatively
conservative between species of plasmodium and had two
highly conservative segments. GAMA was synthesized as
precursor protein and then was processed for two segments
using protease digestion, which was in accordance with
reports in literature [22,23]. In addition, bioinformatic prediction
indicated that GAMA had better antigenic properties, which
could stimulate the body to produce speciﬁc immune
responses. Recently, individual immune serum of attenuated
sporozoite was irradiated by X-ray, GAMA was screened as
pre erythrocyte-stage antigen and had value of vaccine
research [31].
Anti-malarial protection was related with Th1 and Th2
mediated immune responses. Th1 cell produced the IL-2 and
IFN-g and adjusted the producing of IgG2a; while Th2 cell
secreted the IL-4, IL-5, IL-10 and IL-13 and assisted the
secretion of antibody IgG1 and IgE [32]. In our study, IFN-g, IL-
4, IgG1 and IgG2a levels were signiﬁcantly increased, compared
with control group. In addition, IFN-g responses were more
obvious than IL-4 responses, with approximately 4 times of
increase. These results indicated that PbGAMA immunization
could stimulate the body to produce speciﬁc immune responses
and DNA immunization could produce relatively stronger Th1
assistant immune responses. A few preventive effects which
were observed at pre erythrocyte-stage may be related with such
immune responses.
In our study, recombinant GAMA DNA vaccine was inoc-
ulated, which produced antigen speciﬁc immune responses, but
could not play better preventive effect on the invasion of
P. berghei and did not induce the immunity of transmission-
blocking. Although mechanism (immunoprotection could not
be built) has not be clear yet in this paper, possible reasons were
as followed: With reference to anti circumsporozoite protein
antibody, when antibody titer was 51 U/mL, it had 50% of ef-
ﬁcacy for preventing from children infection and clinical cases
[33]. Therefore, a large number of high afﬁnity antibodies were
necessary to reach physiological measurable anti-malarial ef-
fect. Also, the access of invasion between mediated parasites and
host was various and was overlapped functionally [34]. GPI-
anchored proteins was overlapped functionally [35,36]. In such
circumstances, antibody combined with deciduous GAMA
could reduce the antibody mediated cytotoxic effect. What's
more, translation codon should be considered. AT content was
higher in plasmodium gene group and codon optimization
could promote the expression of DNA vaccine in vivo and
could increase the antigen responses [37]. Besides, we thought
that the opportunity of antibody mediated transmission-
blocking effect should be very important. Complement andphagocytes were included in vertebrate animal host components
which inhibited the zygote survival in blood meal [38,39]. In the
internal environment of mosquito stomach, the effects of these
factors would be reduced gradually. Therefore, antigen
expressed at the early sexual stage may have better
transmission-blocking effect. Immunological effect dynamics
in the mosquito stomach derived from vertebrate animal hosts
has not been reported yet. The opportunity of GAMA expression
at sexual stage was also need to be conﬁrmed in the future.
The role and importance of GAMA were different in different
plasmodium. The GAMA gene of Plasmodium falciparum 3D7
and W2mef could not be knocked out, while isogenous GAMA
gene of P. berghei could be knocked out [20–22]. We also found
similar phenomena that compared with P. berghei, DNA vaccine
immunity had more obvious preventive effect on erythrocyte-
stage invasion of P. yoelii. Under similar antibody responses,
the preventive effect on P. berghei was more difﬁcult to reach,
compared with P. yoelii [40]. This difference between P. berghei
and P. yoelii could be used to partly explain why ideal
immunoprotection against to P. berghei has not been built yet.
What's more, some antigens could arouse effective
immunoprotection responses alone. However, these antigens
combined with other antigens could signiﬁcantly increase the
immunoprotection responses [41]. Anti GAMA antibody
combined with anti erythrocyte-binding antigen 175 antibody
had obvious high-level transmission-blocking ability for
erythrocyte-stage invasion [22] and had a certain protective
efﬁcacy at pre-erythrocytic stage. Therefore, further GAMA
vaccine research should not be excluded.
In conclusion, the feasibility of GAMA as candidate vaccine
also needed a further exploration. Experimental analysis of its
applicability and value in multicomponent combined vaccine
was necessary. Besides, it was necessary to change the immu-
noassay platforms to guide other effect mechanisms.
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